Cell line · CVCL_1679
SBC-5
Cancer cell line, Homo sapiens. Thoracic SMARCA4-deficient undifferentiated tumor. 35 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. SBC-5. Cell lines, record CVCL_1679. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1679
On this page
Cell line
As Cellosaurus gives it.
- Name
- SBC-5
- Accession
- CVCL_1679
- RRID
- RRID:CVCL_1679
- Synonyms
- SBC5
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 65Y
- Category
- Cancer cell line
- Diseases
- Thoracic SMARCA4-deficient undifferentiated tumor (NCIt C183115)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Caution | Originally classified as originating from a lung small cell carcinoma, but is reclassified as a thoracic SMARCA4-deficient undifferentiated tumor based on a number of criteria (PubMed=38180245). |
Source Cellosaurus
Papers35
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators. | Sci Adv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. | Clin Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Near-infrared photoimmunotherapy targeting GPR87: Development of a humanised anti-GPR87 mAb and therapeutic efficacy on a lung cancer mouse model. | EBioMedicine | 2021 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 35
See all 35 papersRelatives0
None in this release.
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| JCRB | JCRB0819 |
Source JCRB
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1679
GET https://conductscience.org/api/cell-lines/v1/CVCL_1679/papers?page=2